Detecting early cardiomyopathy in transthyretin variant carriers: reappraising the diagnostic value of Perugini grade 1 radiotracer uptake on bone scintigraphy
Authors:
Open Access
- 23 May 2025
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (13) , 5000-5005
Abstract
Purpose: To determine whether TTRv carriers with Perugini grade 1 cardiac radiotracer uptake on [ 99m Tc]Tc- hydroxydiphosphonate bone scintigraphy have or develop ATTR-CM. Methods: This retrospective observational study was conducted at the Groningen Amyloidosis Centre of Expertise between April 2012 and June 2023. TTRv carriers with Perugini grade 1 uptake on bone scintigraphy were followed until to June 2024. Data on symptoms, biomarkers, imaging, and biopsies were collected. A descriptive analysis was performed to evaluate whether carriers met the diagnostic criteria for ATTR-CM or ‘probable ATTR-CM’ at baseline and follow-up. Results: Out of 178 TTRv carriers in screening, 12 carriers had Perugini grade 1 cardiac radiotracer uptake on bone scintigraphy. At baseline, 2 carriers met the diagnostic criteria for ATTR-CM and 3 carriers met the criteria for probable ATTR-CM. Of the 7 carriers without (probable) ATTR-CM at baseline, 3 carriers were diagnosed with ATTR-CM during follow-up and 1 carrier developed probable ATTR-CM during follow-up. Three carriers showed signs of cardiomyopathy during follow-up, but did not meet the criteria for (probable) ATTR-CM. One of these cases may have been false-positive due to hydroxychloroquine use. Conclusion: Our findings suggest that Perugini grade 1 cardiac radiotracer uptake is an early marker of ATTR-CM in TTRv carriers, potentially enabling earlier diagnosis and intervention.Keywords
All Related Versions
This publication has 10 references indexed in Scilit:
- Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosisEuropean Heart Journal, 2023
- Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid CardiomyopathyCirculation: Heart Failure, 2022
- Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial DiseasesEuropean Heart Journal, 2021
- Serial scanning with 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid (99mTc-DPD) for early detection of cardiac amyloid deposition and prediction of clinical worsening in subjects carrying a transthyretin gene mutationJournal of Nuclear Cardiology, 2019
- Hereditary transthyretin amyloidosis: a model of medical progress for a fatal diseaseNature Reviews Neurology, 2019
- Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic PeptideThe American Journal of Cardiology, 2018
- Nonbiopsy Diagnosis of Cardiac Transthyretin AmyloidosisCirculation, 2016
- Bone scintigraphy with99mtechnetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosisAmyloid, 2013
- Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspectiveEuropean Heart Journal, 2012
- Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99m Tc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid ScintigraphyJACC, 2005